Policy
Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the biotech’s investigational COVID-19 and HIV drug, which artificially inflated its share price.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
In 2010, China launched the “Thousand Talents Plan,” which is aimed at attracting top researchers from across the globe.The government of China is reportedly asking officials to quiet down promotion of the program aimed at recruiting western scientists to work in that country.
Opioid drugmakers being sued in the state of Connecticut are breathing a big sigh of relief today after a judge dismissed lawsuits filed by 37 different municipal governments.
Valio’s consumer-packaged infant formulas have received an export permit from the Chinese authorities.
Swiss pharma giant Novartis has found itself at the center of a legal battle that could determine if the company engaged in a research project that was a kickback in disguise.
Tuesday, January 8, was another busy day in San Francisco for the JP Morgan Healthcare Conference. One interesting sideline was the idea that the current government shutdown could complicate some deals.
Medigene AG reported today that an additional European Patent was granted for its dendritic cell (DC) vaccine platform.
Federal corporate tax cuts that were framed as a way to give a boost to employment across the United States have been more beneficial to companies and shareholders than the average worker or consumer, a new report issued by the advocacy group Americans for Tax Fairness shows.
Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.
According to reports, FDA Commissioner Scott Gottlieb will outline the formation of the Office of Drug Evaluation Sciences, a 52-member group, during his talk at the J.P. Morgan Healthcare Conference in San Francisco later today.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.